Overview

This trial is active, not recruiting.

Condition wuchereria bancrofti infection
Treatment ivermectin, diethylcarbamazine albendazole (ida)
Phase phase 1
Sponsor University Hospitals Cleveland Medical Center
Collaborator Washington University School of Medicine
Start date April 2016
End date March 2017
Trial size 66 participants
Trial identifier NCT02845713, 03-16-09

Summary

The study will be an open label cohort study with 2 two-treatment groups 2). Both groups will be treated with a single oral administration of Diethylcarbamazine (DEC) 6 mg/kg + Albendazole (ALB) 400 mg + Ivermectin (IVR) 200 µg/kg (IDA). One treatment group will include men and women with W. bancrofti infections (>50 Mf/ml, N=30). The other treatment group will include men and women who are free of W. bancrofti infection based on negative blood tests for both microfilariae (Mf) and circulating filarial antigen (N=30). Active follow-up for adverse events (AE) will be for 72hrs and passive follow-up for 7 days following treatment.

Participants will be followed again at 1 year to evaluate treatment efficacy. Individuals with severe AEs (grade 3 or higher) will be transported to the Agboville District Hospital and cared for by the hospital staff. Based on treatment of over 100 Lymphatic filariasis (LF) infected individuals any AEs develop within the first 72 hours following treatment and uncommonly up to 7 days post-treatment.

All individuals will be admitted to a single health center or hospital in Côte d'Ivoire.

Subjects will be monitored for 72-hours after treatment for safety and to facilitate sampling for drug analyses and safety tests. Participants will undergo clinical monitoring every 6 hours to evaluate potential adverse effects of Ivermectin + Diethylcarbamazine + Albendazole (IDA) treatment. Participants will also be monitored for hematologic, or biochemical abnormalities during the period of observation.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification pharmacokinetics/dynamics study
Intervention model parallel assignment
Masking open label
Arm
(Active Comparator)
Single oral dose of Ivermectin, Diethylcarbamazine Albendazole (IDA) W. bancrofti infections positive
ivermectin, diethylcarbamazine albendazole (ida) IDA
To evaluate the safety and tolerability of triple drug therapy (a single dose of ALB, IVM and DEC)
(Active Comparator)
Single oral dose of Ivermectin, Diethylcarbamazine Albendazole (IDA) in 40 individuals who are free of W. bancrofti infection.
ivermectin, diethylcarbamazine albendazole (ida) IDA
To evaluate the safety and tolerability of triple drug therapy (a single dose of ALB, IVM and DEC)

Primary Outcomes

Measure
Drug Levels
time frame: up to 12 hours

Secondary Outcomes

Measure
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 (aggregate)
time frame: up to 1 year
Impact of treatment on Hematuria and Proteinuria
time frame: up to 7 days
Number worm nests
time frame: up to 1 year
Impact of treatment on Liver Function +
time frame: up to 7 days
Impact of treatment on Hemoglobin Levels
time frame: up to 7 days
Impact of treatment on White Blood Cells
time frame: up to 7 days

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: - Willingness to provide informed consent to participation in the study - Male or female 18-65 years of age - Peripheral blood microfilaremia levels >50 microfilaria/ml (treatment group 1) - No evidence of filarial infection by Mf and Circulating filarial antigen (CFA) testing (treatment group 2) - No history of taking anti-filarial medications in past 2 years Exclusion Criteria: Known chronic illness, e.g. tuberculosis, diabetes, renal insufficiency - Anemia (Hb <7 g/dl) by HemaCue - Not willing or able to give informed consent for the study - Onchocerciasis rapid test (Ov16) and/or skin snip positive for onchocerciasis - Permanent disability that prevents or impedes study participation and/or comprehension Pregnancy. Women will be tested with a rapid urine test for beta human chorionic gonadotropin (β-HCG) - Biochemical abnormalities as indicated by liver function tests, and/or creatinine >1.5 times above upper limit of the normal range. - Receiving any routine medications that may interfere with test drug metabolism that cannot be stopped one week prior to onset of study - Evidence of urinary tract infection as indicated by an active urinary sediment (>6- 8 pus/neutrophil cells per field) or 3+ nitrate on dipstick. Individuals without a gross active sediment 1 or 2 plus nitrate or with 1 + protein will not be excluded. Similarly individuals with 1+ haemoglobin on dipstick or trace amount of blood in the will not be excluded. - Lactose and/or gluten intolerance.

Additional Information

Official title Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose Treatment With Diethylcarbamazine, Albendazole and Ivermectin in Humans With and Without Wuchereria Bancrofti Infection in Côte d'Ivoire
Description The study will be an open label cohort study with 2 two-treatment groups. Both groups will be treated with a single oral administration of DEC 6 mg/kg + ALB 400 mg + IVR 200 µg/kg (IDA). One treatment group will include men and women with W. bancrofti infections (>50 Mf/ml, N=30). The other treatment group will include men and women who are free of W. bancrofti infection based on negative blood tests for both microfilariae and circulating filarial antigen (N=30). Active follow-up for adverse events (AE) will be for 72 hours and passive follow-up for 7 days following treatment. Participants will be followed again at 1 year to evaluate treatment efficacy. Individuals with severe AEs (grade 3 or higher) will be transported to the Agboville District Hospital and cared for by the hospital staff. Based on treatment of over 100 LF infected individuals any AEs develop within the first 72 hours following treatment and uncommonly up to 7 days post-treatment. All individuals will be admitted to a single health center or hospital in Côte d'Ivoire. Subjects will be monitored for 72-hours after treatment for safety and to facilitate sampling for drug analyses and safety tests. Participants will undergo clinical monitoring every 6 hours to evaluate potential adverse effects of IDA treatment. Participants will also be monitored for hematologic, or biochemical abnormalities during the period of observation. At enrollment all subjects will be otherwise healthy adult men and women (≥18-65 years of age). All individuals will be assessed for the presence and burden of geohelminth infections, parasitic worms of the gastrointestinal tract such as hookworm, Trichuris trichiuria and Ascaris lumbricoides. This is important because two of the drugs in the combination (ALB and IVM) are active against geohelminths. Individuals with heavy geohelminth burdens may experience adverse reactions because of rapid killing of their intestinal parasites.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by University Hospitals Cleveland Medical Center.